About Kindred Biosciences (NASDAQ:KIN)
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:KIN
- CUSIP: N/A
- Web: www.kindredbio.com
Capitalization:- Market Cap: $221.31 million
- Outstanding Shares: 27,837,000
Average Prices:- 50 Day Moving Avg: $7.73
- 200 Day Moving Avg: $7.42
- 52 Week Range: $3.90 - $9.65
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.81
- P/E Growth: -0.16
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $3.07 per share
- Price / Book: 2.49
Profitability:- EBITDA: ($24,990,000.00)
- Return on Equity: -37.00%
- Return on Assets: -35.40%
Debt:- Current Ratio: 29.87%
- Quick Ratio: 29.87%
Misc:- Average Volume: 105,597 shs.
- Beta: 0.19
- Short Ratio: 2.39
Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
How were Kindred Biosciences' earnings last quarter?
Kindred Biosciences, Inc. (NASDAQ:KIN) issued its quarterly earnings results on Monday, August, 7th. The company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.
When will Kindred Biosciences make its next earnings announcement?
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?
5 brokers have issued twelve-month price objectives for Kindred Biosciences' stock. Their forecasts range from $7.50 to $10.50. On average, they anticipate Kindred Biosciences' share price to reach $9.00 in the next year. View Analyst Ratings for Kindred Biosciences.
Who are some of Kindred Biosciences' key competitors?
Some companies that are related to Kindred Biosciences include Seres Therapeutics (MCRB), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals Holdings (CRBP), Kura Oncology (KURA), AVEO Pharmaceuticals (AVEO), NantKwest (NK), CymaBay Therapeutics (CBAY), UROGEN PHARMA (URGN), Bellicum Pharmaceuticals (BLCM), RA PHARMCTL INC (RARX), GlycoMimetics (GLYC), BioSpecifics Technologies Corp (BSTC), Merus N.V. (MRUS), Geron Corporation (GERN), Edge Therapeutics (EDGE), ObsEva SA (OBSV), Minerva Neurosciences (NERV) and BioTime (BTX).
Who are Kindred Biosciences' key executives?
Kindred Biosciences' management team includes the folowing people:
- Wendy Wee, Chief Financial Officer
- Denise M. Bevers, Chief Operating Officer, Secretary
- Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer
- Herbert D. Montgomery, Independent Director
- Raymond Townsend, Independent Director
- Ervin Veszpremi, Independent Director
How do I buy Kindred Biosciences stock?
Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kindred Biosciences' stock price today?
One share of Kindred Biosciences stock can currently be purchased for approximately $7.65.
MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $9.00 (17.65% upside) |
Consensus Price Target History for Kindred Biosciences (NASDAQ:KIN)
Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/16/2017 | Aegis | Initiated Coverage | Buy | $10.50 | High |  |
| 5/31/2017 | FBR & Co | Reiterated Rating | Buy | | Low | |
| 5/15/2017 | BMO Capital Markets | Reiterated Rating | Hold | $8.00 | N/A | |
| 1/3/2017 | Feltl & Co. | Reiterated Rating | Strong-Buy | | N/A | |
| 11/1/2016 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy | $7.50 | N/A | |
(Data available from 10/24/2015 forward)
Earnings History for Kindred Biosciences (NASDAQ:KIN)Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.33) | | | | | N/A | |
| 8/7/2017 | Q2 2017 | ($0.33) | ($0.29) | | | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.34) | ($0.30) | | | View | Listen | |
| 3/1/2017 | Q416 | ($0.36) | ($0.29) | | | View | Listen | |
| 11/7/2016 | Q316 | ($0.36) | ($0.29) | | | View | Listen | |
| 8/8/2016 | Q216 | ($0.32) | ($0.25) | | | View | N/A | |
| 3/2/2016 | Q415 | ($0.44) | ($0.32) | | | View | N/A | |
| 11/9/2015 | Q3 2015 | ($0.44) | ($0.36) | | | View | N/A | |
| 8/10/2015 | Q2 | ($0.42) | ($0.35) | | | View | N/A | |
| 5/8/2015 | Q115 | ($0.40) | ($0.34) | | | View | N/A | |
| 3/12/2015 | Q414 | ($0.40) | ($0.34) | | | View | N/A | |
| 11/13/2014 | Q3 2014 | ($0.43) | ($0.31) | | | View | N/A | |
| 8/13/2014 | Q2 2014 | ($0.35) | ($0.42) | | | View | N/A | |
| 5/12/2014 | Q1 14 | ($0.18) | ($0.38) | | | View | N/A | |
| 3/6/2014 | | ($0.21) | ($0.40) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS
Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ:KIN)Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 60.37%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/12/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 600,000 | $7.50 | $4,500,000.00 | |
| 7/3/2017 | Richard Chin | Insider | Sell | 13,000 | $8.26 | $107,380.00 | |
| 6/22/2017 | Richard Chin | Insider | Sell | 13,000 | $7.75 | $100,750.00 | |
| 6/8/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 15,311 | $6.65 | $101,818.15 | |
| 5/11/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 155,076 | $6.83 | $1,059,169.08 | |
| 3/15/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 400,000 | $6.60 | $2,640,000.00 | |
| 3/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 4,200 | $6.20 | $26,040.00 | |
| 3/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 18,066 | $6.08 | $109,841.28 | |
| 1/13/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 1,690,000 | $6.20 | $10,478,000.00 | |
| 1/9/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 131,500 | $5.30 | $696,950.00 | |
| 1/6/2017 | Park West Asset Management Llc | Major Shareholder | Buy | 110,617 | $5.10 | $564,146.70 | |
| 12/16/2016 | Park West Asset Management Llc | Insider | Sell | 18,000 | $4.78 | $86,040.00 | |
| 12/14/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 8,334 | $4.75 | $39,586.50 | |
| 12/13/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 1,148 | $4.75 | $5,453.00 | |
| 12/12/2016 | Park West Asset Management Llc | Major Shareholder | Buy | 3,112 | $4.74 | $14,750.88 | |
| 3/15/2016 | Ernest Mario | Director | Buy | 30,000 | $3.55 | $106,500.00 | |
| 11/23/2015 | Raymond Townsend | Director | Buy | 2,000 | $4.00 | $8,000.00 | |
| 11/18/2015 | Raymond Townsend | Director | Buy | 2,323 | $4.78 | $11,103.94 | |
| 8/31/2015 | Raymond Townsend | Director | Buy | 1,677 | $5.85 | $9,810.45 | |
| 8/14/2015 | Raymond Townsend | Director | Buy | 3,000 | $6.04 | $18,120.00 | |
| 9/29/2014 | Oleg Nodelman | Director | Buy | 100,000 | $9.56 | $956,000.00 | |
| 9/3/2014 | Ernest Mario | Director | Buy | 10,000 | $10.55 | $105,500.00 | |
| 8/28/2014 | Oleg Nodelman | Director | Buy | 47,000 | $10.85 | $509,950.00 | |
| 8/26/2014 | Oleg Nodelman | Director | Buy | 85,244 | $10.50 | $895,062.00 | |
| 12/12/2013 | Kevin Schultz | Insider | Buy | 4,000 | $7.00 | $28,000.00 | |
| 12/12/2013 | Oleg Nodelman | Director | Buy | 400,000 | $7.00 | $2,800,000.00 | |
| 12/12/2013 | Stephen Sundlof | SVP | Buy | 1,000 | $7.00 | $7,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Kindred Biosciences (NASDAQ:KIN)
Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
| Source: |
|
Loading headlines, please wait.
Kindred Biosciences (KIN) Chart for Tuesday, October, 24, 2017
